NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) is expected to be releasing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.48) per share and revenue of $1.8770 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The firm had revenue of $3.04 million during the quarter. On average, analysts expect NewAmsterdam Pharma to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
NewAmsterdam Pharma Price Performance
Shares of NewAmsterdam Pharma stock opened at $27.98 on Wednesday. NewAmsterdam Pharma has a one year low of $21.14 and a one year high of $42.21. The firm has a market capitalization of $3.27 billion, a price-to-earnings ratio of -15.63 and a beta of 0.08. The business has a 50-day simple moving average of $32.61 and a 200 day simple moving average of $32.78.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on NewAmsterdam Pharma
Insiders Place Their Bets
In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 105,000 shares of NewAmsterdam Pharma stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the completion of the transaction, the chief accounting officer owned 24,353 shares in the company, valued at approximately $738,870.02. The trade was a 81.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders have sold 210,000 shares of company stock valued at $6,713,550. 12.74% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the stock. Wells Fargo & Company MN boosted its position in shares of NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after buying an additional 300 shares during the last quarter. Empowered Funds LLC purchased a new stake in NewAmsterdam Pharma in the 4th quarter valued at $85,000. Persistent Asset Partners Ltd purchased a new stake in NewAmsterdam Pharma in the 4th quarter valued at $138,000. The Manufacturers Life Insurance Company lifted its stake in NewAmsterdam Pharma by 5.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after acquiring an additional 544 shares in the last quarter. Finally, Guggenheim Capital LLC bought a new position in NewAmsterdam Pharma during the 4th quarter valued at $224,000. Institutional investors own 89.89% of the company’s stock.
About NewAmsterdam Pharma
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
Read More
- Five stocks we like better than NewAmsterdam Pharma
- UPS Just Gave Investors a Second Chance to Buy
- Welltower at 52-Week Highs—But Analysts Believe There’s More to Come
- D-Wave’s AT&T Deal Shows Quantum Computing Is Moving Beyond Theory
- Insiders Sell, Institutions Buy: The AI Trade Is Getting More Interesting
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
